Cargando…

LBODP092 Proposal Of Indication For Completion Thyroidectomy In Follicular Thyroid Carcinoma Using TERT Promoter Mutational Status

BACKGROUND: Stepwise surgical approach with hemithyroidectomy and completion thyroidectomy was used to solve the dilemma of definite characterization of follicular thyroid carcinoma (FTC). However, which patients will be candidates for completion thyroidectomy has been controversial. The aim of this...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Hyunju, Heo, Jung, Ki, Chang-Seok, Shin, Jung Hee, Oh, Young Lyun, Son, Young I, Kim, Jee Soo, Kim, Sun Wook, Chung, Jae Hoon, Kim, Tae Young, Kim, Tae Hyuk, Kim, Jung-Han
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625808/
http://dx.doi.org/10.1210/jendso/bvac150.1522
_version_ 1784822593850703872
author Park, Hyunju
Heo, Jung
Ki, Chang-Seok
Shin, Jung Hee
Oh, Young Lyun
Son, Young I
Kim, Jee Soo
Kim, Sun Wook
Chung, Jae Hoon
Kim, Tae Young
Kim, Tae Hyuk
Kim, Jung-Han
author_facet Park, Hyunju
Heo, Jung
Ki, Chang-Seok
Shin, Jung Hee
Oh, Young Lyun
Son, Young I
Kim, Jee Soo
Kim, Sun Wook
Chung, Jae Hoon
Kim, Tae Young
Kim, Tae Hyuk
Kim, Jung-Han
author_sort Park, Hyunju
collection PubMed
description BACKGROUND: Stepwise surgical approach with hemithyroidectomy and completion thyroidectomy was used to solve the dilemma of definite characterization of follicular thyroid carcinoma (FTC). However, which patients will be candidates for completion thyroidectomy has been controversial. The aim of this study is to clarify the selection criteria for completion thyroidectomy using TERT promoter mutation. METHODS: A total of 87 FTC patients who had information about TERT promoter mutation from August 1995 to November 2020 were investigated. The cumulative risk of initial distant metastasis, disease recurrence, and cancer-specific death according to primary tumor size in each of the WHO 2017 classifications were calculated. RESULTS: Of the 87 patients, 8 patients (9.2%) had initial distant metastasis, and 15 patients (17.2%) had persistent disease or developed structural recurrence. Threshold diameter for initial distant metastasis, disease recurrence, and cancer-specific death was 2cm in minimally invasive FTC (MI-FTC) with mutant TERT (M-TERT) and in encapsulated angioinvasive FTC (EA-FTC) with M-TERT, while in MI-FTC with wild-type TERT (WT-TERT) and EA-FTC with WT-TERT it was 4cm. Cumulative risk of initial distant metastasis, disease recurrence, and cancer-specific death according to primary tumor size in each WHO 2017 classification were significantly different only in patients with WT-TERT (P = 0. 001, P = 0. 019, and P = 0. 005, respectively). CONCLUSIONS: The data suggested that 2 cm may be a critical threshold diameter for deciding completion thyroidectomy in MI-FTC with M-TERT and EA-FTC with M-TERT. TERT promoter mutational status can be a game changer for selecting candidates for completion thyroidectomy. Presentation: No date and time listed
format Online
Article
Text
id pubmed-9625808
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-96258082022-11-14 LBODP092 Proposal Of Indication For Completion Thyroidectomy In Follicular Thyroid Carcinoma Using TERT Promoter Mutational Status Park, Hyunju Heo, Jung Ki, Chang-Seok Shin, Jung Hee Oh, Young Lyun Son, Young I Kim, Jee Soo Kim, Sun Wook Chung, Jae Hoon Kim, Tae Young Kim, Tae Hyuk Kim, Jung-Han J Endocr Soc Thyroid BACKGROUND: Stepwise surgical approach with hemithyroidectomy and completion thyroidectomy was used to solve the dilemma of definite characterization of follicular thyroid carcinoma (FTC). However, which patients will be candidates for completion thyroidectomy has been controversial. The aim of this study is to clarify the selection criteria for completion thyroidectomy using TERT promoter mutation. METHODS: A total of 87 FTC patients who had information about TERT promoter mutation from August 1995 to November 2020 were investigated. The cumulative risk of initial distant metastasis, disease recurrence, and cancer-specific death according to primary tumor size in each of the WHO 2017 classifications were calculated. RESULTS: Of the 87 patients, 8 patients (9.2%) had initial distant metastasis, and 15 patients (17.2%) had persistent disease or developed structural recurrence. Threshold diameter for initial distant metastasis, disease recurrence, and cancer-specific death was 2cm in minimally invasive FTC (MI-FTC) with mutant TERT (M-TERT) and in encapsulated angioinvasive FTC (EA-FTC) with M-TERT, while in MI-FTC with wild-type TERT (WT-TERT) and EA-FTC with WT-TERT it was 4cm. Cumulative risk of initial distant metastasis, disease recurrence, and cancer-specific death according to primary tumor size in each WHO 2017 classification were significantly different only in patients with WT-TERT (P = 0. 001, P = 0. 019, and P = 0. 005, respectively). CONCLUSIONS: The data suggested that 2 cm may be a critical threshold diameter for deciding completion thyroidectomy in MI-FTC with M-TERT and EA-FTC with M-TERT. TERT promoter mutational status can be a game changer for selecting candidates for completion thyroidectomy. Presentation: No date and time listed Oxford University Press 2022-11-01 /pmc/articles/PMC9625808/ http://dx.doi.org/10.1210/jendso/bvac150.1522 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Thyroid
Park, Hyunju
Heo, Jung
Ki, Chang-Seok
Shin, Jung Hee
Oh, Young Lyun
Son, Young I
Kim, Jee Soo
Kim, Sun Wook
Chung, Jae Hoon
Kim, Tae Young
Kim, Tae Hyuk
Kim, Jung-Han
LBODP092 Proposal Of Indication For Completion Thyroidectomy In Follicular Thyroid Carcinoma Using TERT Promoter Mutational Status
title LBODP092 Proposal Of Indication For Completion Thyroidectomy In Follicular Thyroid Carcinoma Using TERT Promoter Mutational Status
title_full LBODP092 Proposal Of Indication For Completion Thyroidectomy In Follicular Thyroid Carcinoma Using TERT Promoter Mutational Status
title_fullStr LBODP092 Proposal Of Indication For Completion Thyroidectomy In Follicular Thyroid Carcinoma Using TERT Promoter Mutational Status
title_full_unstemmed LBODP092 Proposal Of Indication For Completion Thyroidectomy In Follicular Thyroid Carcinoma Using TERT Promoter Mutational Status
title_short LBODP092 Proposal Of Indication For Completion Thyroidectomy In Follicular Thyroid Carcinoma Using TERT Promoter Mutational Status
title_sort lbodp092 proposal of indication for completion thyroidectomy in follicular thyroid carcinoma using tert promoter mutational status
topic Thyroid
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625808/
http://dx.doi.org/10.1210/jendso/bvac150.1522
work_keys_str_mv AT parkhyunju lbodp092proposalofindicationforcompletionthyroidectomyinfollicularthyroidcarcinomausingtertpromotermutationalstatus
AT heojung lbodp092proposalofindicationforcompletionthyroidectomyinfollicularthyroidcarcinomausingtertpromotermutationalstatus
AT kichangseok lbodp092proposalofindicationforcompletionthyroidectomyinfollicularthyroidcarcinomausingtertpromotermutationalstatus
AT shinjunghee lbodp092proposalofindicationforcompletionthyroidectomyinfollicularthyroidcarcinomausingtertpromotermutationalstatus
AT ohyounglyun lbodp092proposalofindicationforcompletionthyroidectomyinfollicularthyroidcarcinomausingtertpromotermutationalstatus
AT sonyoungi lbodp092proposalofindicationforcompletionthyroidectomyinfollicularthyroidcarcinomausingtertpromotermutationalstatus
AT kimjeesoo lbodp092proposalofindicationforcompletionthyroidectomyinfollicularthyroidcarcinomausingtertpromotermutationalstatus
AT kimsunwook lbodp092proposalofindicationforcompletionthyroidectomyinfollicularthyroidcarcinomausingtertpromotermutationalstatus
AT chungjaehoon lbodp092proposalofindicationforcompletionthyroidectomyinfollicularthyroidcarcinomausingtertpromotermutationalstatus
AT kimtaeyoung lbodp092proposalofindicationforcompletionthyroidectomyinfollicularthyroidcarcinomausingtertpromotermutationalstatus
AT kimtaehyuk lbodp092proposalofindicationforcompletionthyroidectomyinfollicularthyroidcarcinomausingtertpromotermutationalstatus
AT kimjunghan lbodp092proposalofindicationforcompletionthyroidectomyinfollicularthyroidcarcinomausingtertpromotermutationalstatus